Are there gender-related differences in the therapeutic management of patients suffering from inflammatory bowel disease? Subgroup analysis of a propspective multicentre online-based trial;Gibt es geschlechtsspezifische behandlungsunterschiede bei patienten mit chronisch entzündlichen darmerkrankungen? Eine subgruppenanalyse einer prospektiven, multizentrischen, online-basierten studie

Zeitschrift fur Gastroenterologie

Volumn 47, Issue 10, 2009, Pages 1045-1051

  Blumenstein, Irina ^a   Bock, H ^b   Zosel, C ^a   Dignass, A U ^c   Hartmann, F ^d   Zeuzem, S ^a   Stein, J M ^e   Schroeder, O ^a  

^a GOETHE UNIVERSITY   (Germany)

^b QGH Qualitätszirkel Gastroenterologie Hessen ^*  (Germany)

^c Markus Krankenhaus Frankfurter Diakonie Kliniken   (Germany)

^d St Marienkrankenhaus   (Germany)

^e Innere Medizin   (Germany)

Author keywords

Chronic inflammatory bowel disease; Crohn's disease; Therapeutic management; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CASE MANAGEMENT; CLINICAL TRIAL; COHORT ANALYSIS; CROHN DISEASE; DRUG USE; FEMALE; GERMANY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNET; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; REMISSION; SEX DIFFERENCE; ULCERATIVE COLITIS; URBAN AREA;

FEMALE; GERMANY; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERNET; MALE; PREVALENCE; PROSPECTIVE STUDIES; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 70450208452     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109647     Document Type: Article

References (23)

1. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics 2002; 20: 639-652
2. Hay JW, Hay AR. Inflammatory bowel disease:costs-of-illness. J Clin Gastroenterol 1992; 14(4): 309-319
3. Blumenstein I, Bock H, Weber C et al. Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study. Inflamm Bowel Dis 2008; 14: 53-60 (Pubitemid 351196869)
4. Shaw LJ, Shaw RE, Merz CN et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 2008; 117: 1787-1801
5. Wirehn AB, Ostgren CJ, Carstensen JM. Age and gender differences in the impact of diabetes on the prevalence of ischemic heart disease: a population-based register study. Diabetes Res Clin Pract 2008; 79: 497-502
6. Tillmanns H, Waas W, Voss R et al. Gender differences in the outcome of cardiac interventions. Herz 2005; 30: 375-389 (Pubitemid 41238955)
7. Bassi A, Dodd S, Williamson P et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471-1478 (Pubitemid 39265268)
8. Ebinger M, Leidl R, Thomas S et al. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J Gastroenterol Hepatol 2004; 19: 192-199 (Pubitemid 38253360)
9. Odes S, Vardi H, Friger M et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006; 131: 719-728 (Pubitemid 44307060)
10. Competence Network IBD (Kompetenznetz-CED). Homepage of the Competence Network IBD. URL http://www.kompetenznetz-ced.de 2007
11. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489
12. Hindorf U, Lindqvist M, Peterson C et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55: 1423-1431 (Pubitemid 44476786)
13. Sandborn WJ, Tremaine WJ, Wolf DC North American Azathioprine Study Group.. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology 1999; 117: 527-535
14. Herrlinger KR, Jewell DP. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2006; 24: 1403-1412
15. Priest VL, Begg EJ, Gardiner SJ et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006; 24: 767-781
16. Dubinsky MC, Reyes E, Ofman J et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005; 100: 2239-2247
17. Hoffmann JC, Autschbach F, Bokemeyer B et al. Short version of the updated German S3 (level 3) guideline on diagnosis and treatment of Crohn's disease. Dtsch Med Wochenschr 2008; 133: 1924-1929
18. Stange EF, Travis SP, Vermeire S et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 Suppl 1: i1-15
19. Travis SP, Stange EF, Lemann M et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 Suppl 1: i16-i35
20. Kroser J, Srinivasan R. Drug therapy of inflammatory bowel disease in fertile women. Am J Gastroenterol 2006; 101: S633-S639 (Pubitemid 44902631)
21. Ediger JP, Walker JR, Graff L et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102: 1417-1426 (Pubitemid 46976288)
22. Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008; 27: 1157-1166 (Pubitemid 351697281)
23. Lau A, Chande N, Ponich T et al. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2008; 28: 606-613